NCT01002495撤回1 期
A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- The primary study objective is to evaluate safety and tolerability of a catheter-based, endocardial injection of different doses of VM202.
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of catheter based injections of VM202 into the heart.
详细描述
A phase I/II, open label, dose-escalation, multicenter, 12 month study designed to assess the safety and tolerability of catheter based percutaneous myocardial injection of VM202 in patients with chronic refractory myocardial ischemia. The study will consist of three (3) cohorts with a total of 4 subjects enrolled in each cohort. Endocardial injections will be performed with the MyoStar Injection Catheter under guidance of the NOGA XP Cardiac Navigation System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 21 years, but less than or equal to 75 years.
- •Stable chronic refractory angina classified as Canadian Cardiovascular Society (CCS) functional class II - IV
- •Left ventricular ejection fraction (LVEF) of ≥30% and ≤ 50%;
- •Clinical signs and symptoms of significant ischemia by treadmill test or Stress imaging (SPECT, Echo or CARDIAC MRI acceptable)
- •Subjects must be able to complete a minimum of 3 minutes, but no more than 10 minutes on a Modified Bruce treadmill protocol.
- •Patients on maximal medical therapy including at least 2 of the following (unless hemodynamic parameters or intolerance contraindicate their use):(a) Long acting nitrate, (b) Beta Blocker or (c) Calcium Channel Blocker (d) Ranolazine. Optimal medical regimen for each subject will be decided by the referring cardiologist or principal investigator. Patients must be on stable medical regimen for 30 days prior to enrollment.
- •Coronary angiogram within 1 year to confirm the presence of coronary disease which is not amenable to standard revascularization procedures.
- •Candidates must not be eligible for any other revascularization procedures. The participant and his/her coronary film must have been discussed with an independent cardiac surgeon and must have been denied for CABG or PTCA. Participants who are marginal or poor candidates for conventional revascularization will be considered eligible if the risks of performing a CABG or PTCA procedure outweigh the potential benefit and/or such a procedure is unlikely to offer a worthwhile clinical benefit. The criteria defining such cases may include, but may not be limited to, the following examples:
- •Diffuse or distal vessel disease
- •Chronic occlusions
- •Unprotected left main stenosis
- •Tortuous or severely angulated vessels
- •Severely calcified vessels
- •Small vessels (< 2.5mm)
- •Subjects with childbearing potential must take acceptable measure to prevent pregnancy during the course of the study.
- •Subject capable of understanding with the protocol and signing the informed consent document prior to any study related procedure.
排除标准
- •Subjects who have undergone a successful revascularization procedure within 6 months of enrollment;
- •MI, unstable angina requiring > 24 hour hospitalization, or percutaneous coronary intervention, within last 90 days;
- •Stroke or TIA within last 180 days;
- •Predominant CHF symptoms;
- •Hemodynamically significant severe primary valvular heart disease, unless corrected by a properly functional prosthetic valve;
- •Uncontrolled hypertension as defined as systolic BP 170 mmHg or diastolic > 90 mmHg at baseline/ screening evaluation;
- •Sustained ventricular tachycardia or automatic implantable cardiodefibrillator (AICD) firing within last 180 days;
- •History of ventricular fibrillation;
- •Use of the MyoStar catheter may not be appropriate for patients with prosthetic valves. Patients with a mechanical valve at risk for injury due to the interventional approach should be excluded;
- •Subjects with any comorbidity that may interfere with the ability to perform a maximal treadmill test (e.g. severe arthritis, musculoskeletal disorders, COPD);
- •Subjects with a history of malignancy, a known active malignancy, or a new screening finding of malignant neoplasm;
- •Patients with family history of colon cancer in any first degree relative unless they have undergone a colonoscopy in the last 12 months with negative findings;
- •Elevated PSA unless prostate cancer has been excluded;
- •Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination.
- •Cataract surgery within 6 months of trial;
- •Vascular lesions of the anterior segment of the eye (infection or ulceration of the cornea, rubeotic glaucoma, etc);
- •Vascular lesions of the posterior segment of the eye or proliferative retinopathy in diabetics, macular edema, s/p photocoagulation for macular edema or proliferative retinopathy; nondiabetics with central or branch retinal vascular occlusions, sickle cell retinopathy, ischemic retinopathy due to retinal venous stasis or carotid artery disease);
- •Choroidal new vessels associated with age-related macular degeneration, myopic degeneration, presumed ocular histoplasmosis syndrome, angioid streaks, pseudoxanthoma elasticum, or without ocular disease; and
- •Large elevated choroidal nevi, choroidal vascular tumors (choroidal hemangioma), or melanomas.
- •Chronic inflammatory disease (e.g. Crohn, Rheumatoid Arthritis);
- •Active infectious disease and/or known to have tested positive for human immunodeficiency virus (HIV), human t lymphotrophic virus (HTLV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- •Specific laboratory values at Screening including: Hemoglobin < 9.0, g/dL, WBC < 3,000 cells per microliter, platelet count <75,000/mm3, Creatinine > 2.0 mg/dL, AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary;
- •Patients have undergone enhanced external pulsation (EECP) treatment within the last 6 months;
- •Pregnancy or lactation;
- •Severe comorbidity associated with a reduction of life expectancy of less than 1 year;
- •Exposure to any previous experimental angiogenic therapy and/or myocardial laser therapy; or therapy with another investigational drug within 180 days of enrollment or participation in any concurrent study that may confound the results of this study;
- •Major psychiatric disorder in past 6 months;
- •History of recent tobacco abuse (within past < 5 years);
- •Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
研究组 & 干预措施
Cohort 1
Experimental
Eight endocardial injection for a total dose of 1mg VM202
干预措施: VM202 (Biological)
Cohort 2
Experimental
Eight endocardial injections for a total dose of 2mg VM202
干预措施: VM202 (Biological)
Cohort 3
Experimental
Twelve endocardial injections for a total dose of 3mg VM202
干预措施: VM202 (Biological)
结局指标
主要结局
The primary study objective is to evaluate safety and tolerability of a catheter-based, endocardial injection of different doses of VM202.
时间窗: Days 1, 7, 14, 21, 30, 60, and 90, 6 and 12 months
次要结局
- Efficacy measures include exercise treadmill test, SPECT, cardiac MRI and change in use of anti-anginal medications.(Days 1, 7, 14, 21, 30, 60, and 90. 6 and 12 months)
- Secondary objectives include the assessment of the angiogenic potential of VM202(one month, three months, six months and twelve months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of VM202 to Treat Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT02039401Helixmith Co., Ltd.18
已完成
1 期
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic TumorsNonhematologic Neoplasms, AdvancedNCT02699749Millennium Pharmaceuticals, Inc.80
终止
1 期
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)Dermatitis, AtopicNCT04220411Arjil Pharmaceuticals LLC17
已完成
1 期
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU PatientsUrticaria ChronicNCT03632291United BioPharma15
已完成
1 期
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid TumorsNeoplasms, Advanced SolidNCT02525536Takeda18